π PRO: This Week in Visuals
The article is a PRO weekly roundup of business and earnings visuals, highlighting multiple public companies. It includes a detailed Eli Lilly section: Q2 revenue rose 48% Y/Y to $23.0B, adjusted EPS was $8.38, and GLP-1 sales grew with Mounjaro and Zepbound. Lilly raised FY26 revenue guidance to $85β$87B.
How this was made
The 30-second read
Why it matters
For LLY, the actionable elements are the raised FY26 revenue and EPS guidance, the volume-driven GLP-1 growth (including international expansion), and the initial commercial traction of Foundayo plus Phase 3 readouts for retatrutide.
Market read
Traders can update LLY forward estimates based on the guidance raise and the stated drivers (volume growth offsetting realized price declines).
What to watch
Foundayoβs $98M first-quarter sales are early; retatrutide Phase 3 progress is promising but not yet a revenue driver, so the market may overreact to pipeline headlines versus near-term cash flow.
Background
The piece is a PRO-style weekly roundup, but it includes a detailed, company-specific update for Eli Lillyβs Q2 results, GLP-1 product performance, pipeline progress, and FY26 guidance.
Ticker impact
Eli Lilly raised FY26 revenue guidance to $85β$87B and EPS guidance at the midpoint, citing volume growth and GLP-1 mix changes.
Likely positive bias for LLY as traders price in higher FY26 revenue/EPS, with sensitivity to realized-price declines and acquisition-related R&D charges.
The article provides specific, time-relevant guidance updates and segment/product growth figures (volume, international expansion, Foundayo sales) that directly affect forward estimates.
Market effects
Reinforces the GLP-1 obesity demand narrative as a volume-led growth model, potentially supporting sentiment across obesity drug peers.
International Mounjaro expansion despite price reductions highlights ongoing geographic scaling dynamics for GLP-1 supply and reimbursement.
Signals continued global access expansion for obesity therapies, which can influence broader healthcare growth expectations.
Counterpoint
Raised guidance may still mask margin pressure from deliberate price concessions and acquisition-related R&D charges, so upside could be capped if reimbursement or pricing worsens faster than volume growth.
Key entities
- companyEli Lilly
Reports Q2 revenue/EPS beats, volume-led GLP-1 growth, Foundayo early sales, retatrutide Phase 3 progress, and raises FY26 guidance.
